Body PSOriasis: Long-term Relapse CONTROL
- Conditions
- Psoriasis Vulgaris
- Registration Number
- NCT03402828
- Lead Sponsor
- LEO Pharma
- Brief Summary
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 764
- Patients planned to receive topical treatment of any kind to prevent relapse of symptoms
- Written informed consent
- Contraindications to selected treatment
- Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time of relapse Up to 52 weeks Length of relapse free period after start of maintenance strategy
- Secondary Outcome Measures
Name Time Method Dermatology Life Quality Index Up to 52 weeks Standard QoL measure within dermatology
PGA (physician's global assessment of symptoms) Up to 52 weeks 5-point verbal rating scale
PsGA (patient's global assessment of symptoms) Up to 52 weeks 5-point verbal rating scale
Trial Locations
- Locations (1)
The State Autonomous Foundation of Public Health "Republic Clinical Dermatovenereological Dispensary" of the Republic of Tatarstan
🇷🇺Kazan, Tatarstan, Russian Federation